Since the introduction of chemotherapy for the treatment of childhood leukemia more than sixty years ago, the, prognosis for children with cancer has improved dramatically. The 5-year survival rate for childhood cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now approaching.80%. Despite these advances, several childhood cancers still have unacceptably low cure rates, and even when treatment is successful, the acute and long-term morbidity of current therapy can be substantial. The Children's Oncology Group (COG), the world's largest organization devoted exclusively to childhood and adolescent cancer research, was founded 12 years ago. The COG's multidisciplinary research team, comprised of more than 8,000 members, conducts research at more than 200 leading children's hospitals, universities, and cancer centers. This proposal is for COG, as part of NCI's new National Clinical Trials Network, to continue its collaborative research work that supports the mission of improving the outcome for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic approaches that range from targeted, small molecules to cellular therapies. As more than 90% of children diagnosed with cancer in the US are treated at COG member institutions, the COG has the ability to offer to children with cancer and their families to participation in research that allows for collection and annotation of biospecimens from all children with cancer, providing the foundation for discovery and accelerating the most promising research efforts conducted in laboratories around the world. The COG research portfolio importantly also includes research trials focused on improving the quality of life children with cancer and survivors. The proposal is for support of the COG Group Operations Center, clinician-scientists who develop and conduct research, and for member sites to participate through enrollment of eligible subjects.
The Children's Oncology Group (COG) is the world's largest organization devoted exclusively to childhood and adolescent cancer research. Over 200 leading children's hospitals, universities, and cancer centers across North America participate in COG research, which is focused on developing better treatments for all children with cancer.
|Williams, Lindsay A; Pankratz, Nathan; Lane, John et al. (2018) Klinefelter syndrome in males with germ cell tumors: A report from the Children's Oncology Group. Cancer 124:3900-3908|
|Hawkins, Douglas S; Chi, Yueh-Yun; Anderson, James R et al. (2018) Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol 36:2770-2777|
|Dix, David B; Seibel, Nita L; Chi, Yueh-Yun et al. (2018) Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 36:1564-1570|
|Roberts, Kathryn G; Reshmi, Shalini C; Harvey, Richard C et al. (2018) Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. Blood 132:815-824|
|Smolik, Suzanne; Arland, Lesley; Hensley, Mary Ann et al. (2018) Assessment Tools for Peripheral Neuropathy in Pediatric Oncology: A Systematic Review From the Children's Oncology Group. J Pediatr Oncol Nurs 35:267-275|
|Rodgers, Cheryl; Bertini, Vanessa; Conway, Mary Ashe et al. (2018) A Standardized Education Checklist for Parents of Children Newly Diagnosed With Cancer: A Report From the Children's Oncology Group. J Pediatr Oncol Nurs 35:235-246|
|Omidakhsh, Negar; Bunin, Greta R; Ganguly, Arupa et al. (2018) Parental occupational exposures and the risk of childhood sporadic retinoblastoma: a report from the Children's Oncology Group. Occup Environ Med 75:205-211|
|DiNofia, Amanda M; Seif, Alix E; Devidas, Meenakshi et al. (2018) Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232. Cancer Med 7:3-12|
|Fernandez, Conrad V; Mullen, Elizabeth A; Chi, Yueh-Yun et al. (2018) Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. J Clin Oncol 36:254-261|
|Pishas, Kathleen I; Drenberg, Christina D; Taslim, Cenny et al. (2018) Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Mol Cancer Ther 17:1902-1916|
Showing the most recent 10 out of 322 publications